General Announcement::GPL commences 1000 patients Post Marketing Surveillance study with COVID-19

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
13-Jul-2020 14:20:17
Status
New
Announcement Sub Title
GPL commences 1000 patients Post Marketing Surveillance study with COVID-19
Announcement Reference
SG200713OTHR2CU4
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
13/07/2020 00:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark commences 1000 patients Post Marketing Surveillance study with COVID-19 who are administered FabiFlu

Also, due to better yield and scale, Glenmark passes the benefits to patients by reducing the price of oral antiviral FabiFlu by 27 % in India

Attachments

SGX_PR_13072020.pdf
Total size =1187K